In contrast, the Cu(BDC)/ChS nanocomposite presented here combines a MOF with the tumor-targeting capability of ChS, enabling both active (via CD44 receptor) and passive (via pH-sensitivity) targeting with controlled release properties. The gene discussed is LYST; the disease is neoplasm.